查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1577094

至 2030 年肌萎縮側索硬化症 (ALS) 藥物市場預測：按藥物類型、作用機制、給藥途徑、階段、應用、最終用戶和地區進行的全球分析

Amyotrophic Lateral Sclerosis Therapeutics Market Forecasts to 2030 - Global Analysis By Drug Type, Action Mechanism, Route Of Administration, Disease Stage, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球肌萎縮側索硬化症（ALS）治療藥物市場規模為 8.6 億美元，預計 2030 年將達到 23.1 億美元，預測期內的複合年成長率為 12.6%。

肌萎縮側索硬化症 (ALS) 是神經退化性疾病，其治療藥物包括多種旨在控制症狀、減緩疾病進展和改善 ALS 患者生活品質的治療方法。治療藥物可緩解肌肉無力、痙攣和疼痛等症狀，提升患者的舒適度和生活品質。

根據美國疾病管制與預防中心 (CDC) 發病率和死亡率週報中發布的資料，2015美國美國發現了約 16,583 例肌萎縮側索硬化症病例。

發病率增加

隨著越來越多的患者被診斷為 ALS，對有效治療方法的需求將會增加，從而推動研發投資。製藥公司積極創新，從而引入新的治療方法和臨床試驗。此外，提高對 ALS 的認知和支持將導致對研究計劃的資助和支持增加。患者數量的增加，加上對疾病認知的進步，透過促進有針對性的個人化治療方法的發展，正在推動成長。

複雜的控制途徑

肌萎縮側索硬化症 (ALS) 治療的複雜調控途徑是由於疾病的罕見性和多效性。大規模臨床試驗的需要，通常涉及不同的患者群體，可能會延遲藥物核准。證明功效和安全性的嚴格要求使這一過程更加複雜。因此，新療法上市的延遲限制了患者的治療選擇並阻礙了整體市場的成長。

越來越重視多學科治療和支持性護理

ALS 治療方法整合了神經病學、呼吸治療、營養和安寧療護，以改善患者的生活品質和治療結果。協作護理模式促進了綜合治療計劃的製定，並推動了對創新治療和支持性干預措施的需求。此外，人們對 ALS 認知的提高以及對個人化護理的需求正在推動研究投資和夥伴關係，從而導致新型治療方法的出現。這種整體方法提高了患者的依從性和滿意度，進一步推動市場成長。

治療費用高

治療 ALS 的高昂費用是由於疾病的複雜性、對先進藥物的需求以及持續的支持性護理。創新療法通常供應有限，並且需要大量研發投資，從而推高了價格。這些高成本限制了患者的治療機會，造成了經濟負擔，並降低了對治療方法的依從性。這將限制患者數量並減少 ALS 藥物的整體需求，影響新產品開發和市場開拓潛力並阻礙市場成長。

COVID-19 的影響

COVID-19 大流行擾亂了臨床試驗和研究活動，並推遲了新治療方法的開發和核准，對 ALS 藥物市場產生了重大影響。患者在取得醫療服務方面面臨挑戰，導致治療方法中斷並減少患者監測。此外，對 COVID-19 的關注耗盡了 ALS 研究的資源和資金。然而，大流行已經普及了遠端醫療，它可以提供持續的患者支持和諮詢，並可能有助於 ALS 患者的長期照護策略。

Riluzole細分預計在預測期間規模最大

預計Riluzole細分市場將在整個預測期內獲得最大的市場佔有率。Riluzole是 FDA認證核可藥。它被歸類為麩胺酸拮抗劑，透過抑制麩胺酸，谷氨酸是一種神經傳導物質，過量時會導致神經細胞損傷。Riluzole已被證明可以減緩 ALS 患者的疾病進展並延長存活期，使其成為重要的治療選擇。

預計實驗療法在預測期內將經歷最高的複合年成長率

預計實驗治療領域將在預測期內表現出最高的複合年成長率。透過針對疾病的潛在機制，ALS 的實驗性治療方法已顯示出希望。透過專注於個人化醫療，這些實驗性治療旨在改善患者的治療結果和生活品質。此外，我們也致力於加深對 ALS 的了解，為未來的突破鋪路，並擴大 ALS 患者的治療方法前景。

比最大的地區

由於該疾病的認知不斷提高和患病率不斷上升，預計亞太地區在預測期內將佔據最大的市場佔有率。日本、中國和印度等國家正在專注於加強有效治療方法的研究和發展。旨在改善醫療基礎設施和患者獲得治療機會的政府措施進一步支持市場擴張。此外，對支持性護理的日益重視也加強了該地區 ALS 的整體管理。

複合年成長率最高的地區：

由於先進的醫療基礎設施和研發方面的大量投資，預計北美在預測期內的複合年成長率最高。美國和加拿大在創新治療方法的臨床試驗方面處於領先地位，特別是基因療法和新藥物配方。大型製藥公司的出現加劇了競爭，並加速了有效 ALS治療方法的開發。此外，全面的支持性護理服務可改善患者的治療效果和生活品質。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球肌萎縮側索硬化症（ALS）藥物市場：依藥物類型

  • Riluzole
  • Edaravone
  • 臨床實驗藥物
  • 其他藥物類型

第6章 全球肌萎縮側索硬化症 (ALS) 治療藥物市場：按作用機制

  • 麩胺酸抑制劑
  • 自由基清除劑
  • 神經保護劑
  • 聯合治療
  • 其他作用機制

第7章全球肌萎縮側索硬化症（ALS）治療藥物市場：依給藥途徑

  • 口服
  • 靜脈
  • 皮下的
  • 肌肉注射

第8章全球肌萎縮側索硬化症（ALS）治療藥物市場：依疾病階段分類

  • 早期的
  • 中期
  • 晚期

第9章全球肌萎縮側索硬化症（ALS）治療藥物市場：依應用分類

  • 症狀治療
  • 營養支持
  • 呼吸治療
  • 物理和職業治療
  • 實驗性治療方法
  • 補充療法
  • 其他用途

第 10 章 全球肌萎縮側索硬化症 (ALS) 治療市場：依最終使用者分類

  • 醫院
  • 專科診所
  • 家庭護理設置
  • 調查機構
  • 其他最終用戶

第11章全球肌萎縮側索硬化症（ALS）治療藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、合作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章 公司概況

  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly and Company
  • Amgen Inc.
  • Sanofi
  • Biogen Inc.
  • Ionis Pharmaceuticals Inc.
  • Orphazyme A/S
  • Regeneron Pharmaceuticals Inc.
  • Reata Pharmaceuticals Inc.
  • Apellis Pharmaceuticals Inc.
  • Wave Life Sciences Limited
  • Cytokinetics Incorporated
  • NeuroSense Therapeutics Limited
  • Coya Therapeutics
Product Code: SMRC27403

According to Stratistics MRC, the Global Amyotrophic Lateral Sclerosis Therapeutics Market is accounted for $0.86 billion in 2024 and is expected to reach $2.31 billion by 2030 growing at a CAGR of 12.6% during the forecast period. Amyotrophic Lateral Sclerosis (ALS) therapeutics encompass a range of treatments aimed at managing symptoms, slowing disease progression, and improving quality of life for individuals with ALS, a neurodegenerative disorder affecting motor neurons in the brain and spinal cord. Therapeutics help alleviate symptoms such as muscle weakness, spasticity, and pain, improving patient comfort and quality of life.

According to the data published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, in 2015 around 16,583 cases of amyotrophic lateral sclerosis were identified in the USA.

Market Dynamics:

Driver:

Increasing incidence rates

As more individuals are diagnosed with ALS, the demand for effective treatment options rises, driving research and development investments. Pharmaceutical companies are incentivized to innovate, leading to the introduction of novel therapies and clinical trials. Furthermore, heightened awareness and advocacy for ALS lead to increased funding and support for research initiatives. This growing patient population, coupled with advancements in understanding the disease, fuels market expansion by promoting the development of targeted and personalized treatment solutions.

Restraint:

Complex regulatory pathways

Complex regulatory pathways in Amyotrophic Lateral Sclerosis (ALS) therapeutics stem from the disease's rarity and its multifaceted nature. The need for extensive clinical trials, often involving diverse patient populations, can delay drug approvals. Stringent requirements for demonstrating efficacy and safety further complicate the process. Consequently, the slow progression of novel therapies reaching the market limits treatment options for patients and hampers overall market growth.

Opportunity:

Growing emphasis on multidisciplinary care and supportive therapies

ALS therapeutics approach integrates neurology, respiratory therapy, nutrition, and palliative care, enhancing patient quality of life and treatment outcomes. Collaborative care models promote the development of comprehensive treatment plans, driving demand for innovative therapeutics and supportive interventions. Additionally, heightened awareness of ALS and the need for personalized care encourage research investments and partnerships, leading to the emergence of novel therapies. This holistic approach fosters greater patient adherence and satisfaction, further propelling market growth.

Threat:

High treatment costs

High treatment costs in ALS therapeutics stem from the complexity of the disease, the need for advanced medications, and ongoing supportive therapies. Innovative treatments, often in limited supply, require significant research and development investment, resulting in elevated prices. These high costs can limit patient access, create financial burdens, and reduce adherence to treatment regimens. Consequently, this hampers market growth by restricting the patient population and reducing overall demand for ALS therapeutics, thus impacting the potential for new product development and market expansion.

Covid-19 Impact

The covid-19 pandemic significantly impacted the ALS therapeutics market by disrupting clinical trials and research activities, delaying the development and approval of new therapies. Patients faced challenges in accessing healthcare services, leading to interrupted treatment regimens and decreased patient monitoring. Additionally, the focus on COVID-19 diverted resources and funding away from ALS research. However, the pandemic also increased telehealth adoption, allowing for continued patient support and consultations, potentially benefiting long-term care strategies for ALS patients.

The riluzole segment is expected to be the largest during the forecast period

The riluzole segment is predicted to secure the largest market share throughout the forecast period. Riluzole is an FDA-approved drug used in the treatment of Amyotrophic Lateral Sclerosis (ALS). It is classified as a glutamate antagonist, working primarily by inhibiting the release of glutamate, a neurotransmitter that can contribute to neuronal damage when present in excess. Riluzole is shown to slow disease progression and extend survival in ALS patients, making it a critical therapeutic option.

The experimental therapies segment is expected to have the highest CAGR during the forecast period

The experimental therapies segment is anticipated to witness the highest CAGR during the forecast period. Experimental therapies for ALS offer promising benefits by targeting the disease's underlying mechanisms. By focusing on personalized medicine, these experimental treatments aim to enhance patient outcomes and quality of life. Moreover, they contribute to a deeper understanding of ALS, paving the way for future breakthroughs and expanding the therapeutic landscape for affected individuals.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness of the disease and rising incidence rates. Countries like Japan, China, and India are focusing on enhancing research and development efforts for effective therapies. Government initiatives aimed at improving healthcare infrastructure and patient access to treatments further support market expansion. Additionally, the growing emphasis on supportive care options enhances the overall management of ALS in this region.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period driven by advanced healthcare infrastructure and significant investment in research and development. The United States and Canada are leading in clinical trials for innovative therapies, with a focus on gene therapy and novel drug formulations. The presence of major pharmaceutical companies enhances competition and accelerates the development of effective ALS therapies. Additionally, comprehensive supportive care services improve patient outcomes and quality of life.

Key players in the market

Some of the key players profiled in the Amyotrophic Lateral Sclerosis Therapeutics Market include Teva Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., Eli Lilly and Company, Amgen Inc., Sanofi, Biogen Inc., Ionis Pharmaceuticals Inc., Orphazyme A/S, Regeneron Pharmaceuticals Inc., Reata Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Wave Life Sciences Limited, Cytokinetics Incorporated, NeuroSense Therapeutics Limited and Coya Therapeutics.

Key Developments:

In August 2024, NeuroSense Therapeutics Ltd. announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM), which evaluated the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS). This data provides additional insights that align with the Company's recent announcements of improved survival by 43% and slowed disease progression by 36%.

In June 2024, Coya Therapeutics recently announced the publication of a Phase 1 clinical trial that evaluated a novel combination therapy for Amyotrophic Lateral Sclerosis (ALS) in the peer-reviewed journal Frontiers in Neurology. The study explored the effects of a combination of CTLA4-Ig and low-dose interleukin-2 (IL-2) on ALS patients.

Drug Types Covered:

  • Riluzole
  • Edaravone
  • Investigational Drugs
  • Other Drug Types

Action Mechanisms Covered:

  • Glutamate Inhibitors
  • Free Radical Scavengers
  • Neuroprotective Agents
  • Combination Therapies
  • Other Action Mechanisms

Route Of Administrations Covered:

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular

Disease Stages Covered:

  • Early Stage
  • Moderate Stage
  • Advanced Stage

Applications Covered:

  • Symptomatic Treatments
  • Nutritional Support
  • Respiratory Therapies
  • Physical & Occupational Therapy
  • Experimental Therapies
  • Complementary Therapies
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Riluzole
  • 5.3 Edaravone
  • 5.4 Investigational Drugs
  • 5.5 Other Drug Types

6 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Action Mechanism

  • 6.1 Introduction
  • 6.2 Glutamate Inhibitors
  • 6.3 Free Radical Scavengers
  • 6.4 Neuroprotective Agents
  • 6.5 Combination Therapies
  • 6.6 Other Action Mechanisms

7 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Route Of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Subcutaneous
  • 7.5 Intramuscular

8 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Disease Stage

  • 8.1 Introduction
  • 8.2 Early Stage
  • 8.3 Moderate Stage
  • 8.4 Advanced Stage

9 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Application

  • 9.1 Introduction
  • 9.2 Symptomatic Treatments
  • 9.3 Nutritional Support
  • 9.4 Respiratory Therapies
  • 9.5 Physical & Occupational Therapy
  • 9.6 Experimental Therapies
  • 9.7 Complementary Therapies
  • 9.8 Other Applications

10 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Homecare Settings
  • 10.5 Research Institutions
  • 10.6 Other End Users

11 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Teva Pharmaceutical Industries Limited
  • 13.2 Novartis AG
  • 13.3 Pfizer Inc.
  • 13.4 Eli Lilly and Company
  • 13.5 Amgen Inc.
  • 13.6 Sanofi
  • 13.7 Biogen Inc.
  • 13.8 Ionis Pharmaceuticals Inc.
  • 13.9 Orphazyme A/S
  • 13.10 Regeneron Pharmaceuticals Inc.
  • 13.11 Reata Pharmaceuticals Inc.
  • 13.12 Apellis Pharmaceuticals Inc.
  • 13.13 Wave Life Sciences Limited
  • 13.14 Cytokinetics Incorporated
  • 13.15 NeuroSense Therapeutics Limited
  • 13.16 Coya Therapeutics

List of Tables

  • Table 1 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Drug Type (2022-2030) ($MN)
  • Table 3 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Riluzole (2022-2030) ($MN)
  • Table 4 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Edaravone (2022-2030) ($MN)
  • Table 5 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Investigational Drugs (2022-2030) ($MN)
  • Table 6 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Drug Types (2022-2030) ($MN)
  • Table 7 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Action Mechanism (2022-2030) ($MN)
  • Table 8 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Glutamate Inhibitors (2022-2030) ($MN)
  • Table 9 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Free Radical Scavengers (2022-2030) ($MN)
  • Table 10 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Neuroprotective Agents (2022-2030) ($MN)
  • Table 11 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Combination Therapies (2022-2030) ($MN)
  • Table 12 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Action Mechanisms (2022-2030) ($MN)
  • Table 13 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Route Of Administration (2022-2030) ($MN)
  • Table 14 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Oral (2022-2030) ($MN)
  • Table 15 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Intravenous (2022-2030) ($MN)
  • Table 16 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Subcutaneous (2022-2030) ($MN)
  • Table 17 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Intramuscular (2022-2030) ($MN)
  • Table 18 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Disease Stage (2022-2030) ($MN)
  • Table 19 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Early Stage (2022-2030) ($MN)
  • Table 20 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Moderate Stage (2022-2030) ($MN)
  • Table 21 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Advanced Stage (2022-2030) ($MN)
  • Table 22 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Application (2022-2030) ($MN)
  • Table 23 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Symptomatic Treatments (2022-2030) ($MN)
  • Table 24 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Nutritional Support (2022-2030) ($MN)
  • Table 25 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Respiratory Therapies (2022-2030) ($MN)
  • Table 26 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Physical & Occupational Therapy (2022-2030) ($MN)
  • Table 27 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Experimental Therapies (2022-2030) ($MN)
  • Table 28 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Complementary Therapies (2022-2030) ($MN)
  • Table 29 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 30 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By End User (2022-2030) ($MN)
  • Table 31 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 32 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 33 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Homecare Settings (2022-2030) ($MN)
  • Table 34 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Research Institutions (2022-2030) ($MN)
  • Table 35 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.